BASConfidentialandProprietary.ForInternalEducationalPurposesOnly血管通道器材选择综合评估第一页，共四十九页。BASConfidentialandProprietary.ForInternalEducationalPurposesOnly血管通道器材选择综合评估第二页，共四十九页。BASConfidentialandProprietary.ForInternalEducationalPurposesOnly评估的重要性！第三页，共四十九页。BASConfidentialandProprietary.ForInternalEducationalPurposesOnly通道和血管通道什么是通道?--特指治疗药物进入人体的非口服途径什么是通道?--特指治疗药物进入人体的非口服途径时间性空间性通道的特性体内开口位于血管内的通道是血管通道，于静脉内更多见第四页，共四十九页。BASConfidentialandProprietary.ForInternalEducationalPurposesOnly评估的时间第五页，共四十九页。BASConfidentialandProprietary.ForInternalEducationalPurposesOnlyVascularAccessPlanning血管通路规划“Onadmission,thepatientwillhaveavascularaccessplanthatmeetshis/herneeds.Theplanwillbere-evaluatedatregularintervalsoraspatientconditionchanges〞从治疗伊始，就应该为病人制定一个完善的血管通路规划来满足他的治疗需求。而且这个规划应当随着病人的治疗进展定期的进行再评估和进行必要的调整Barton&Danek.“ImprovingpatientoutcomethruCQIvascularAccessplanning.JNrsgQualCare199813(2)77-85第六页，共四十九页。BASConfidentialandProprietary.ForInternalEducationalPurposesOnly81%78%76%84%82%41%0%20%40%60%80%100%%respodentsQ3b.Chemotherapyagentsmostcommonlyusedinrespondents'practicesNov/Dec2003n=461Taxol(paclitaxel)CisplatinTaxotere(docetaxel)carboplatin)5FU(flourourical)Cytoxan(cyclophosphamide)OtherchManagerTaxolCisplatin泰素顺铂TaxotereParaplatinCytoxan泰索帝〔多西他赛〕伯尔定〔卡铂〕环磷酰胺第七页，共四十九页。BASConfidentialandProprietary.ForInternalEducationalPurposesOnlyQ1.AverageofchemotherapydeliveredthroughvariousVADsNov/Dec2003n=461[duetoestimationerrorthetotaldoesnotequal100%]CVC,8.4%PeripheralIV,31.5%Port,duallumen,9.3%PICC,9.8%Port,singlelumen,43.4%TomBeggs,MarketingResearchManager31.5%patientsgetperipheralchemotherapy315%的病人使用外周血管进行化疗第八页，共四十九页。BASConfidentialandProprietary.ForInternalEducationalP...
